DNA encoding the cancer associated SCM recognition factor

Details DNA encoding the cancer associated SCM recognition factor DNA encoding the cancer associated SCM recognition factor

1993-08-25

1995-08-22

Nucker, Christine M.

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

4351723, 4353201, 530300, 530324, 530325, 530326, 530327, 530328, 530329, 536 231, 536 232, 536 235, 536 243, 536 2431, C12N 512, C12N 1515

Patent

active

054439671

ABSTRACT:
A cancer recognition factor (SCM factor) useful in the performance of the structuredness of the cytoplasmic matrix (SCM) test has been isolated, purified to substantial homogeneity, and characterized, and methods for its use have been described. The factor is a peptide of at least 9 amino acid residues including a core sequence of 9 amino acid residues having an amphipathicity profile substantially equivalent to that of the sequence F-L-M-I-D-Q-N-T-K and produces at least a 10 percent decrease in the intracellular fluorescence polarization value of SCM-responding lymphocytes from donors afflicted with cancer. A synthetic SCM factor representing a consensus sequence of M-I-P-P-E-V-K-F-N-K-P-F-V-F-L-M-I-D-Q-N-T-K-V-P-L-F-M-G-K is fully active. Antibodies specific for SCM factor are useful in immunoassays that can detect the factor, including detection in cancer cells grown in vitro. The SCM factor is useful for screening of blood samples and other body fluids or cell aspirates for the presence of malignancy in the donor. The multiple action spectrum of the SCM factor including cancer proliferation and invasion promotion, as well as inhibition of the host's immune defense mechanisms and synthesis of SCM factor by cancer cells, represents a novel target for cancer management. Methods for reducing in vivo activity of the SCM factor, such as dialysis or antibody neutralization, can also be useful in the management of cancer.

REFERENCES:
patent: 4001080 (1977-01-01), Goust et al.
patent: 4444744 (1984-04-01), Goldenberg
patent: 4645738 (1987-02-01), Knowles et al.
patent: 4657892 (1987-04-01), Brantl
L. Cercek et al., "Biophysical Differentiation Between Lymphocytes from Healthy Donors, Patients with Malignant Diseases and Other Disorders," Brit. J. Cancer 29:345-352 (1974).
L. Cercek & B. Cercek, "Application of the Phenomenon of Changes in the Structuredness of Cytoplasmic Matrix (SCM) in the Diagnosis of Malignant Disorders: a Review," Europ. J. Cancer 13:903-915 (1977).
L. Cercek & B. Cercek, "Changes in SCM-Responses of Lymphocytes in Mice After Implantation with Ehrlich Ascites Cells," Europ. J. Cancer 17:167-171 (1981).
L. Cercek & B. Cercek, "Changes in the SCM Response Ratio (RR.sub.SCM) After Surgical Removal of Malignant Tissue," Brit. J. Cancer 31:250-251 (1975).
L. Cercek & B. Cercek, "Apparent Tumour Specificity with the SCM Test," Brit. J. Cancer 31:252-253 (1975).
S. Chaitchik et al., "Tumour Specificity of the SCM Test for Cancer Diagnosis," Eur. J. Cancer Clin. Oncol. 21:1165-1170 (1985).
J. A. V. Pritchard et al., "A Clinical Assessment of Fluorescence Polarisation Chagnes in Lymphocyte Stimulated by Phytohaemagglutinin (PHA) in Malignant and Benign Diseases," Eur. J. Cancer Clin. Oncol. 18:651-659 (1982).
B. Cercek, "Letter to the Editor," Cancer 53:17A-18A (1984).
L. Cercek & B. Cercek, "Letter to the Editor: Comments on `The SCM Test for Cancer, An Evaluation in Terms of Lymphocytes from Healthy Donors and Cancer Patients' by Mitchell, Wood, Pentycross and Bagshawe, Br. J. Cancer (1980) 41, 772, " Br. J. Cancer 42:947-949 (1980).
H. Orjasaeter et al., "Response of T-Lymphocytes to Phytohaemagglutinin (PHA) and to Cancer-Tissue-Associated Antigens, Measured by the Intracellular Fluorescence Polarization Technique (SCM Test)," Br. J. Cancer 40:628-633 (1979).
L. Cercek & B. Cercek, "Effects of Ascorbate Ions on Intracellular Fluorescein Emission Polarization Spectra in Cancer and Normal Proliferating Cells," Cancer Detection and Prevention 10:1-20 (1987).
S. Stewart et al., "A Flow System Adaptation of the SCM Test for Detection of Lymohocyte Response in Patients with Recurrent Breast Cancer," Clin. Immunol. & Immunopathol. 13:171-181 (1979).
N. D. Schnuda, "Evaluation of Fluorescence Polarization of Human Blood Lymphocytes (SCM Test) in the Diagnosis of Cancer," Cancer 46:1164-1173 (1980).
K. Suzuki & Y. Sasaki, "Studies of Encephalitogenic Fragments of Myelin Protein. IV. Synthesis of Glycine Analogs of Tryptophan-containing Fragment," Chem. Pharm. Bull. 22:2181-2187 (1974).
A. A. Gershokovich et al., "A Study of the Properties of Synthetic Analogs of the Tryptophane-containing Fragment 113-121 of the Basic Protein of Myelin," Khim. Prirod. Soedinen, 4:557-565 (1979) (translated from Russian).
C. M. Deber & M. E. M. Young, "Association of Carbon-13-Enriched Human Encephalitogenic Nonapeptide with a Membrane Surface," J. Biol. Chem. 254:6341-6345 (1979).
C. Blake & B. J. Gould, "Use of Enzymes in Immunoassay Techniques: A Review," Analyst 109:533-547 (1984).
M. Oellerich, "Enzyme-Immunoassay: A Review," J. Clin. Chem. Clin. Biochem. 22:895-904 (1984).
J. L. Marx, "How Cancer Cells Spread in the Body," Science 244:147-148 (1989).
B. W. Hancock & R. C. Rees, "Interluekin-2 and Cancer Therapy," Cancer Cells 2:29-32 (1990).
J. G. Kaplan & C. Bona, "Proteases as Mitogens: The Effect of Trypsin and Pronase on Mouse and Human Lymphocytes," Exp. Cell Res. 88:388-394 (1974).
Y. Shai et al., "Antisense Peptide Recognition of Sense Peptides: Sequence Simplification and Evaluation of Forces Underlying the Interaction," Biochemistry 28:8804-8811 (1989).
G. Fassina et al., "Recognition Properties of Antisense Peptides to Arg.sup.8 -Vasopressin/Bovine Neurophysin II. Biosynthetic Precursor Sequences," Biochemistry 28:8811-8818 (1989).
M. R. Potter & M. Moore, "Natural Cytotoxic Reactivity of Human Lymphocytes," Immunology 37:187-194 (1979).
E. Cameron et al., "The Orthomolecular Treatment of Cancer III. Reticulum Cell Sarcoma: Double Complete Regression Induced by High-Dose Ascorbic Acid Therapy," Chem.-Biol. Interactions 11:387-393 (1975).
N. Bishun et al., "The Effect of Ascorbic Acid (Vitamin C) on Two Tumor Cell Lines in Culture," Oncology 35:160-162 (1978).
S. Bram et al., "Vitamin C Preferential Toxicity for Malignant Melanoma Cells," Nature 284:629-631 (1980).
J. L. Marx, "What T Cells See and How They See It," Science 242:863-865 (1988).
W. Becker, "Determination of Antisera Titres Using the Single Radial Immunodiffusion Method," Immunochemistry 6:539-546 (1969).
R. W. Carrell et al., "Structure and Variation of Human .alpha..sub.1 -Antitrypsin," Nature 298:329-334 (1982).
M. Fagerhol & D. W. Cox, "The Pi Polymorphism: Genetic, Biochemical, and Clinical Aspects of Human .alpha..sub.1 -Antitrypsin," in Advances in Human Genetics (H. Harris & K. Hirschhorn, eds., Plenum Press, New York, 1981), vol. 11, pp. 1-62.
W. Troll et al., "Mechanisms of Protease Action in Carcinogenesis," in Carcinogenesis--A Comprehensive Survey, Vol. II: Mechanisms of Tumor Promotion and Cocarcinogenesis (T. J. Slaga, A. Sivak and R. K. Boutwell, eds., Raven Press, New York, 1978) pp. 301-312.
T. G. Rossman & W. Troll, "Protease Inhibitors in Carcinogenesis: Possible Sites of Action," in Carcinogenesis, Vol. V: Modifiers of Chemical Carcinogenesis (T. J. Slaga, ed., Raven Press, New York, 1980), pp. 127-148.
G. J. Cianciolo, "Anti-Inflammatory Effects of Neoplasia," in Inflammation: Basic Principles and Clinical Correlates (J. I. Gallin, I. M. Goldstein & R. Snyderman, eds., Raven Press, New York, 1988) Ch. 48, pp. 861-874.
E. Reich, "Tumor-Associated Fibrinolysis," Fed. Proc. 32:2174-2175 (1973).
H. B. Bosmann, "Release of Specific Protease During Mitotic Cycle of L5178Y Murine Leukaemic Cells by Sublethal Autolysis," Nature 249:144-145 (1974).
I. Hayashi, & B. I. Carr, "DNA Synthesis in Rat Hepatocytes: Inhibition by a Platelet Factor and Stimulation by an Endogenous Factor," J. Cell Physiol. 125:82-90 (1985).
D. Moscatelli & D. B. Rifkin, "Membrane and Matrix Localization of Proteinases: A Common Theme in Tumor Cell Invasion and Angiogensis," Biochem. Biophys. Acta 948:67-85 (1988).
B. Hagmar et al., "Why Do Tumors Metastasize? An Overview of Current Research," Tumor Biol. 5:141-149 (1984).
C. A. McWherter et al., "Novel Inhibitors of Leukocyte Elastase and Cathepsin G. Sequence Variance of Squash Seed Protease Inhibitor with Altered Protease Selectivity," Biochemistry 28:5708-5714 (1989).
D. C. Linch et al., "Signal Transduction in Human T. Lymphocytes," Immunol. Rev. 95:137-159 (1987).
G. L

Affiliated with

Also associated with

Rating

DNA encoding the cancer associated SCM recognition factor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNA encoding the cancer associated SCM recognition factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA encoding the cancer associated SCM recognition factor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2141237